Kornimate/medical-research-clean huggingface dataset:
hydrogen peroxide fumigation in dental office environment

Conditions: Bacterial Infections; Dental Caries; Aerosol Disease

Summary: the study's null hypothesis posits no significant difference in bacterial levels in the dental office environment before and after implementing hydrogen peroxide (h₂o₂) fumigation. the study comprised 30 participants, 18 females and 12 males, all diagnosed with moderate caries decay (icdas 3 and 4) in their mandibular molars, averaging 42.2 ± 8.3 years in age. sample size calculations for 30 microbiological plates in each group utilized g\*power software (kiel university, germany), factoring in prior research, with a significance level of 0.05, effect size (d) of 0.72, 95% confidence interval, and 85% power. aerobic bacterial content in the dental office air was assessed using the koch sedimentation method. the study employed 60 petri dishes with columbia agar and 5% sheep blood. during caries treatment, thirty plates were opened and sealed 40 minutes later, while another set of thirty plates was opened and closed 60 minutes post-fumigation. measurements were taken 1 meter above the ground and 2 meters from the patient's mouth. after 48 hours of incubation at 37°c, microbiological contamination was calculated as cfus (colony-forming units) in one cubic meter using the formula: l = a × 1000 / (πr² × k). fumigation involved a 20-minute treatment with 6% hydrogen peroxide biosanitizer (saniswiss, switzerland) via a compressed air device (fumi-jet, kormed, poland). the process included 3 minutes of fumigation and a 17-minute waiting period for the chemotoxic effect, with 45 ml of 6% hydrogen peroxide sprayed in a 20 m² room.


Eligibility criteria:
inclusion criteria: * diagnosed with moderate caries decay based on the international caries detection and assessment system (icdas 3 and 4) in their mandibular molar teeth * received hygienist treatment two weeks before the study initiation exclusion criteria: * use anti-inflammatory medications * non-smokers * had systemic illnesses * with uncompensated diabetes * with halitosis symptoms * with gastric diseases
a study of mitoguazone dihydrochloride in patients with aids-related non-hodgkin's lymphoma

Conditions: Lymphoma, Non-Hodgkin; HIV Infections

Summary: to estimate the response rate, response duration, clinical benefit, and toxicity of mitoguazone dihydrochloride (mgbg) in patients with aids-related refractory or relapsing non-hodgkin's lymphoma (nhl).

patients receive infusions of mgbg on days 1 and 8 and every 2 weeks thereafter. it is suggested that a lumbar puncture be performed to evaluate for leptomeningeal disease.

Eligibility criteria:
inclusion criteria patients must have: * hiv positivity by elisa confirmed by western blot. * aids-related nhl that is refractory or relapsed. * life expectancy of at least 12 weeks. exclusion criteria co-existing condition: patients with the following symptoms and conditions are excluded: * concomitant malignancy other than curatively treated carcinoma in situ of the cervix; basal or squamous cell carcinoma of the skin; or non-active, non-visceral kaposi's sarcoma not requiring active chemotherapy. * active uncontrolled bacterial infection, viral infection (other than herpes simplex), or fungal infection (other than oropharyngeal candidiasis) that requires treatment within 2 weeks of study entry. * significant cardiovascular disease. concurrent medication: excluded: * hormonal therapy (except medications given for muscle wasting, such as testosterone or megace). * other chemotherapy. * investigational anti-cancer drugs. concurrent treatment: excluded: * concomitant radiation to sites other than cns. patients with the following prior conditions are excluded: prior malignancy other than curatively treated carcinoma in situ of the cervix; basal or squamous cell carcinoma of the skin; or non-active, non-visceral kaposi's sarcoma not requiring active chemotherapy. recommended: * prophylaxis for pcp and oral candidiasis. required in patients with leptomeningeal disease: * intrathecal methotrexate or cytarabine (ara-c). * leucovorin. required in patients with leptomeningeal disease: cranial radiation to a helmet field.

Keywords: lymphoma, non-hodgkin acquired immunodeficiency syndrome lymphoma, aids-related mitoguazone
specific genotypes/phenotypes of pneumocystis jirovecii in solid organ transplant recipients: potential involvement of mycophenolic acid

Conditions: Transplantation; Pulmonary Diseases

Summary: to determine the presence of imdph mutants of pneumocystis jirovecii in solid organ transplant recipient with prior exposition to mycophenolic acid.

mycophenolic acid (mpa) targets inosine 5'-monophosphate dehydrogenase (impdh) of human lymphocytes. it is used as an immunosuppressant to prevent rejection in solid organ transplant (sot) recipients who are otherwise at risk for pneumocystis pneumonia (pcp). we recently hypothesized that mpa exerts selective pressure on pneumocystis given the in vitro antifungal activity of this drug on other fungi. in a single center study, we identified a missense mutation g1020a in the impdh gene, corresponding to an amino acid change ala261thr in impdh protein, among pneumocystis isolates from mpa-treated sot recipients. considering that the impdh of mpa-resistant candida albicans isolates harbors thr at the analogous position, this mutation was considered to be a marker of pneumocystis strain selection related to mpa exposure. the aim of this study is to strengthen these preliminary results with data from a large multicenter study. the study will be conducted in 26 centers in france. about one hundred patients with pcp will be enrolled. pneumocystis isolates from sot recipients exposed to mpa and from control patients (non-sot recipients, not exposed to mpa) will be examined.the analysis of the impdh gene was combined with a multilocus sequence typing (mlst) method (mtlsurrna, cytochrome b and superoxide dismutase genes) characterized by a high discriminatory power. the expected results may show the presence of the g1020a mutation (ala261thr) in sot recipients exposed to mpa and in none of the control patients not exposed to mpa. this mutation will be significantly associated with mpa exposure. it could also be associated with a specific multilocus genotype in sot patients and none of the control patients. the study will confirm that the g1020a mutation (ala261thr) represents the signature of mpa exposure. the results of the analysis of the impdh gene combined with the mlst will highlight the selection under mpa pressure of specific strains of pneumocystis, which circulate in the population of sot recipients.

Eligibility criteria:
inclusion criteria: * \>= 18 years old with pcp diagnoses, organ transplant recipient or not, acceptation to participate exclusion criteria: * \< 18 years old, no acceptation to participate

Keywords: pneumocystis jirovecii impdh genetic variant
acceptance of telemedicine during the covid-19 pandemic

Conditions: Covid-19

Summary: currently, due to the effects of covid-19 pandemic, there is an imperative need to change the healthcare model. in this regard, telemedicine has proved very useful in health crises, in which there is a possibility of infection between people, offering remote access to medical care. telemedicine has been used in many chronic diseases such as asthma and chronic obstructive pulmonary disease, diabetes mellitus, and appears to be well accepted by patients. however, few studies have been conducted in surgical services and in other diseases. therefore, the aim of this study is to assess the level of acceptance of the patients, in this pandemic situation, to a telemedicine follow-up in different departments. this is an observational, cross-sectional, multicenter and international study with prospective and retrospective data collection. to evaluate patients' acceptance, we used the validated questionnaire telehealth usability questionnaire (tuq). in addition, all patients will provide an overall satisfaction score for telemedicine on a scale from 1 to 5 (1=lowest; 5=highest satisfaction).


Eligibility criteria:
inclusion criteria: * patients contacted by telemedicine (phone and/or video call) during the covid-19 pandemic in outpatient clinics * follow-up of patients with any chronic disease and postoperative patients, preoperative and urgent consultation * age greater than or equal to 18 years exclusion criteria: * patients with cognitive or sensory difficulties or with insufficient comprehension of the language in which the survey is conducted * patients who decline to take part in the telephone survey

Keywords: telemedicine patient acceptance covid-19
moxifloxacin af ophthalmic solution for treatment of bacterial conjunctivitis

Conditions: Bacterial Conjunctivitis

Summary: the purpose of this study is to evaluate the safety and efficacy of moxifloxacin af ophthalmic solution compared to moxifloxacin af vehicle in the treatment of bacterial conjunctivitis in patients one month of age or older.


Eligibility criteria:
inclusion criteria: * diagnosed with bacterial conjunctivitis in 1 or both eyes; * able to understand and sign an informed consent form. if subject is \<18 years of age, the informed consent must be understood and signed by the subject's legally authorized representative; * agrees to comply with the visit schedule and other requirements of the study; * other protocol-specified inclusion criteria may apply. exclusion criteria: * signs and symptoms of bacterial conjunctivitis for longer than 4 days prior to day 1; * presence of concomitant viral infection; * infants with ophthalmia neonatorum of gonococcal, chlamydia, herpetic or chemical origin; * infants whose birth mothers had any sexually transmitted disease within 1 month prior to delivery; * infants undergoing treatment for retinopathy of prematurity; * contact lens wear during the course of the study; * only 1 sighted eye or vision in either eye not correctable to 0.6 logmar units (20/80) or better; * use of medications, as specified in the protocol; * any systemic or ocular disease or disorder, complicating factors or structural abnormality that could negatively affect the conduct or outcome of the study; * known or suspected allergy or hypersensitivity to fluoroquinolones; * pregnant, lactating, or of childbearing potential and not using adequate birth control to prevent pregnancy; * other protocol-specified exclusion criteria may apply.

Keywords: pink eye conjunctivitis moxifloxacin fluoroquinolone
inspiratory muscle training (imt) in athletes

Conditions: Running Endurance

Summary: the purpose of this study is to determine weather well trained athletes benefit from inspiratory (respiratory) muscle training.

* subject: the investigators intend to include 40 well trained runners, 18 years or older. * design: following lung function and exercise testing (incremental treadmill test to exhaustion, 5000m run time trial) participants will be randomly assigned to a verum or a control group. the verum group will train with a hand-held, commercially available pressure threshold loading device (powerbreathe,uk). the control group will perform a sham-training with the same device. after six to eight weeks the the initial tests will be repeated. * hypothesis: inspiratory muscle training enhances performance on submaximal work loads and in the 5000m run time trial by changes in breathing pattern. maximum oxygen uptake remains unchanged.

Eligibility criteria:
inclusion criteria: * well trained runners exclusion criteria: * previous respiratory muscle training * cardiovascular diseases * impaired lung function

Keywords: respiratory muscle breathing pattern exercise performance
system delay and clinical outcome among chinese patients with ami treated with reperfusion therapy (moody study)

Conditions: Coronary Heart Disease

Summary: acute myocardial infarction (ami) pose a pool clinical outcome to men and women whom treatment was delayed. however, reperfusion time was limited in previous studies. to evaluate the system delay and clinical outcomes among chinese patients with ami, consecutive inpatient case prospectively collected from 1999 to 2016. basic data and innovative evidence will accelerate evidence-based clinical practice and policy making, and improve ami patients outcomes finally.

ami is one of the leading causes of mortality and morbidity in public health globally, as well as in china. remarkable variations of repercussion time and clinical outcome have been noted, however little information is available about how shortened d2b time is incorporated appropriately into routine clinical practice in china. in addition, basic data and evidence about effectiveness of treatment for ami during long-term recovery is limited. practical and applied knowledge from large unselected population is needed to guide practice for improvement. this study will enroll patients with a confirmed diagnosis of ami consecutively in china. at study entry, participants will be interviewed during their index hospitalization, to collect information about symptoms, functioning, quality of life, and medical care. demographic characteristics, medical history, clinical features, diagnostic tests, medications, procedures, and in-hospital outcomes of patients will be abstracted from medical records by well trained professional abstractors. at 1 month, and 12 month after discharge, participants will return to the clinic for follow up visits. this study will examine system delay that may affect patients recovery after a heart attack. effective clinic path system, and risk model for ami patients will be established based on the findings, to improve patients outcomes in future finally.

Eligibility criteria:
inclusion criteria: * hospitalized patients with acute myocardial infarction according to positive cardiac biomarkers (troponin i/t, ck-mb or ck≥ local laboratory upper limit of normal values within 24 hours after initial presentation, and at least one of the following two supporting evidence of ischemia (ischemic symptoms occurring within 24 hours before admission or up to 72 hours for stemi; ecg changes indicative of new ischemia). exclusion criteria: * previously enrolled in the similar study

Keywords: acute myocardial infarction
population pharmacokinetics and metabolomics of theophylline in preterm infants

Conditions: Apea of Prematurity

Summary: 1. population pharmacokinetics : the purpose of this study is - to investigate the population pharmacokinetics of theophylline in premature korean infants and to assess the influence of demographic and clinical covariates. 2. metabolomics : the purpose of this study are * to predict serum theophylline levels and to assess cyp1a2 activities in premature infants by analyzing urinary metabolites of theophylline * to examine which factors affect clearance of theophylline and cyp1a2 activity in premature infants


Eligibility criteria:
inclusion criteria: * inborn preterm infants (ga \< 37 weeks) * dx : apnea of prematurity * tx : aminophylline / theophylline * informed consent of parents exclusion criteria: * major congenital anomaly * expired within 72 hours * proven secondary apnea

Keywords: theophylline
bicarbonate in patients with out-of-hospital cardiac arrest

Conditions: Cardiac Arrest; Metabolic Acidosis

Summary: a pilot study to evaluate the effect of sodium bicarbonate administration on cardiopulmonary resuscitation results and outcomes in cardiac arrest patient with severe metabolic acidosis.


Eligibility criteria:
inclusion criteria: * adult cardiac arrest patient with arterial ph \<7.1 or bicarbonate \<10mmeq/l checked at 10 minutes of cardiopulmonary resuscitation exclusion criteria: * age \<18 trauma patient do not resuscitate state

Keywords: sodium bicarbonate
head positions to open the upper airway

Conditions: Apnea; Cardiopulmonary Resuscitation

Summary: ventilation during basic life support improves survival in cardiac arrest patients significantly. unfortunately, this is in contrast to the willingness of potential rescuers to perform mouth-to-mouth ventilation. for example, although healthcare professionals would perform mouth-to-mouth ventilation on a 4-year old drowned child in \>90% of cases, this likelihood would decrease to \~10% in the case of a young male unconscious patient in a san francisco public bus. possibly, lay rescuers would perform assisted ventilation more often if a simple ventilation device were available. however, both the willingness to perform assisted ventilation plus the ability to open and to maintain the airway patent are necessary to ensure efficient ventilation in an unconscious patient with an unprotected upper airway. since retention of skills after basic life support classes are notoriously low, a resuscitation tool should incorporate self-explanatory features to improve applicability, and to provide built-in safety. thus, an option could be to ensure an open airway by the use of a built-in indicator within a ventilating device to confirm correct head extension. one possible approach may be to determine head position angles that make an open airway likely, and integrate these angles into a scale on a ventilating device; however, safe head extension needs to be determined first to prevent harm. the purpose of this study is to determine head position angles and ventilation parameters reflecting neutral position, maximal extension and a position deemed optimal by an anaesthesiologist in patients undergoing anaesthesia induction for elective surgery in a first step to design a ventilating device to optimise ventilation of an unprotected upper airway. the investigators will ventilate 30 patients with a pillow under the head simulating ventilation in the operating theater, and 30 patients without a pillow under the head simulating ventilation during cardiopulmonary resuscitation. dentures will not be removed during assessment. after anaesthesia induction the head will be consecutively flexed in the three positions and measurements performed. afterwards, general anaesthesia and surgery will ensue. the health risk for this extra minutes of mask ventilation is minimal. the null hypothesis is that there will be no differences in head position angles and ventilation parameters.


Eligibility criteria:
inclusion criteria: * asa i and ii exclusion criteria: * cervical spine pathologies * peripheral nerve deficiencies * body mass index \>40kg/m2 * obvious primary or secondary craniofacial abnormalities

Keywords: airway anaesthesia resuscitation ventilation
predicting cognitive and emotional health from neurocircuitry following tbi

Conditions: Traumatic Brain Injury

Summary: abnormalities in structural and functional connectivity between brain regions have been suggested as putative biomarkers of mild traumatic brain injury (tbi) and significant contributors to neuropsychological functioning and injury outcome. the purpose of this study is to use two advanced magnetic resonance imaging (mri) techniques called diffusion-weighted imaging (dwi) and resting state functional mri to compare structural and functional connectivity between individuals with documented mild tbi and healthy controls. to evaluate the significance of structural and functional connectivity for behavior, the brain imaging data will then be related to measures of cognition and emotion. over a 4-year period, 150 adults with documented mild tbi and 30 healthy controls will participate in the study. the study will investigate the following questions and hypotheses: 1. evaluate the dwi metric fractional anisotropy (fa) as a measure of white matter integrity across multiple stages of recovery following mild tbi relative to healthy controls. it is hypothesized that mild tbi will be associated with greater white matter abnormalities than healthy controls. 2. it is hypothesized that there will be a relationship between fa, cognition and emotion as a function of the injury. 3. it is hypothesized that functional connectivity will be related to fa.


Eligibility criteria:
inclusion criteria: * english as first language * ability to provide informed consent * for tbi group: documented tbi experienced within 12 months prior to testing. exclusion criteria: * metal within the body, claustrophobia or other contraindications for mri * complicating medical conditions that may influence the outcome of neuropsychological assessment or neuroimaging (e.g., hiv, brain tumor, etc.) * less than 9th grade education * history of alcoholism or substance use disorder * excess current alcohol use or illicit substance use * for healthy controls (hc): life-time history of tbi or axis i disorder * pregnancy (ruled out by urine β-hcg) * colorblindness * for hc: having participated in a sport with a high risk of concussive/subconcussive blows for a period of at least 1 month including but not limited to: football, rugby, boxing, ice hockey, wrestling, soccer, martial arts

Keywords: traumatic brain injury diffusion weighted imaging resting state functional connectivity cognition
safety and pharmacokinetics of subcutaneous injection of octa101 in adult patients with severe hemophilia a

Conditions: Severe Hemophilia A

Summary: this phase 1/2 study will be a dose escalation study in adults in 5 cohorts (named cohorts 1, 2, 3, 5 and 6), with the main purpose to assess the safety of subcutaneous injection of octa101 (a human-cl rhfviii and recombinant human von willebrand factor fragment dimer) in previously treated adult patients with severe hemophilia a. the study also aims to assess the pharmacokinetics (pk) characteristics, dose proportionality, and subcutaneous bioavailability of octa101 compared with intravenous administration of nuwiq (human-cl rh fviii), in order to define the prophylactic treatment (dose and injection interval) that would result in protective trough levels of fviii:c for future phase 3 studies. cohorts 1, 2, 3 and 5 will undergo a single injection of octa101, with cohorts 1, 2 and 3 proceeding to 3-month daily dosing prophylactic treatment for 3 months by data monitoring committee recommendation. cohorts 1 and 2 will undergo a further pk at the end of the daily injection period. a further cohort, cohort 6, will have an initial 4 to 6-week run-in treatment period with nuwiq intravenous prophylaxis followed by 12.5 iu/kg octa101 subcutaneous daily prophylaxis for \>3 up to 6-7 months.


Eligibility criteria:
inclusion criteria: 1. severe hemophilia a (\<1% fviii:c) as documented in medical records 2. males ≥18 years of age 3. subjects who have had ≥150 exposure days (eds) with a fviii product 4. written informed consent for study participation obtained before undergoing any study specific procedures exclusion criteria: 1. previous participation in this trial 2. use of an investigational medicinal product within 30 days prior to the first octa101 injection 3. history of fviii inhibitors titre ≥0.6 bu/ml defined by medical records 4. inhibitors to fviii (≥0.6 bu/ml) at screening measured by nijmegen modified bethesda method at central laboratory 5. human immunodeficiency virus (hiv) positive subjects with a cd4+ count \<200/ml 6. clinically significant anemia at screening (hemoglobin \<8 g/dl) 7. presence of any significant comorbidity (at the discretion of the investigator) that might confound the interpretation of the study data and/or that might put the patient at undue risk by participating in the trial 8. any coagulation disorder other than hemophilia a 9. ast or alt levels \>3 times the upper limit of normal 10. creatinine \>120 μmol/l 11. platelet count \<100,000 μl 12. bmi ≥30 kg/m² 13. for cohort 6, patients with a positive lumitope test at screening will be excluded

Keywords: hemophilia a blood coagulation disorders, inherited blood coagulation disorders hematologic diseases coagulation protein disorders hemorrhagic disorders genetic diseases, inborn factor viii